GSK Says Ris-Rez Cut Osteosarcoma Progression or Death Risk 67%
GSK said its licensee Hansoh Pharmaceutical Group announced positive results for Ris-Rez in patients with relapsed osteosarcoma in China.
GSK said its licensee Hansoh Pharmaceutical Group announced positive results for Ris-Rez in patients with relapsed osteosarcoma in China.